FDA to discuss drug-induced liver injury

FDA will hold a public meeting March 23 for stakeholders to discuss ways of measuring, evaluating and acting upon drug-induced liver injury and dysfunction in clinical trials. Critical Path Institute (C-Path) will co-sponsor the meeting. ...